Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma
| Autor: | Ryutaro Uchi, Risa Tanaka, Akihiro Tamae, Teppei Noda, Takahiro Wakasaki, Takashi Nakagawa, Nana Tsuchihashi, Kensuke Koike, Ryuji Yasumatsu, Nozomu Matsumoto, Kuniaki Sato, Noritaka Komune |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Skull Neoplasms 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Stable Disease Internal medicine Temporal bone medicine Humans 030223 otorhinolaryngology Aged Neoplasm Staging Retrospective Studies Chemotherapy business.industry Palliative Care Therapeutic effect Temporal Bone General Medicine Middle Aged medicine.disease Survival Analysis Head and neck squamous-cell carcinoma Tumor Burden stomatognathic diseases Nivolumab Otorhinolaryngology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Surgery Neoplasm Recurrence Local business Progressive disease Chemoradiotherapy |
| Zdroj: | Auris Nasus Larynx. 47:864-869 |
| ISSN: | 0385-8146 |
| Popis: | Objective The immune checkpoint inhibitor Nivolumab was approved for the treatment of platinum-refractory head and neck squamous cell carcinoma (SCC), expanding the treatment options for recurrent or advanced head and neck SCC. However, since temporal bone squamous cell carcinoma (TB-SCC) is very rare cancer, the effectiveness of Nivolumab remains unclear. We investigated the effects of Nivolumab for TB-SCC. Method Chart information was collected for all patients who underwent the first administration of Nivolumab for recurrent or residual TB-SCC in our hospital between September 2017 and December 2019. Tumor staging followed the modified Pittsburgh classification. Changes in the tumor burden and survival outcome were examined. Results We examined 9 patients with recurrent or residual TB-SCC who started administration of Nivolumab. In these cases, recurrent or residual SCC was observed after chemotherapy and/or chemoradiotherapy including platinum. The duration of Nivolumab was 2–54 weeks (median 20.0 weeks). The evaluation of the therapeutic effect according to the RECIST method showed partial response in 1 case, stable disease in 2 cases, progressive disease in 4 cases, and size unevaluated in 2 case. Although the number of cases was small, comparing with 5 cases without Nivolumab, these cases showed longer overall survival (1-year OS 33.3% vs 20.0%). Conclusion We used Nivolumab as palliative chemotherapy in 9 patients with recurrent/residual TB-SCC, and we were able to obtain a certain therapeutic effect on TB-SCC as well as other head and neck SCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect